Cargando…

Shenlijia Attenuates Doxorubicin-Induced Chronic Heart Failure by Inhibiting Cardiac Fibrosis

Application of the anticancer drug doxorubicin (DOX) is restricted due to its adverse, cardiotoxic side effects, which ultimately result in heart failure. Moreover, there are a limited number of chemical agents for the clinical prevention of DOX-induced cardiotoxicity. Based on the theories of tradi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xutao, Song, Yunjia, Xie, Ying, Han, Jieru, Chen, Fei, Sun, Yang, Sui, Bowen, Jiang, Deyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310442/
https://www.ncbi.nlm.nih.gov/pubmed/34326887
http://dx.doi.org/10.1155/2021/6659676
_version_ 1783728763433910272
author Sun, Xutao
Song, Yunjia
Xie, Ying
Han, Jieru
Chen, Fei
Sun, Yang
Sui, Bowen
Jiang, Deyou
author_facet Sun, Xutao
Song, Yunjia
Xie, Ying
Han, Jieru
Chen, Fei
Sun, Yang
Sui, Bowen
Jiang, Deyou
author_sort Sun, Xutao
collection PubMed
description Application of the anticancer drug doxorubicin (DOX) is restricted due to its adverse, cardiotoxic side effects, which ultimately result in heart failure. Moreover, there are a limited number of chemical agents for the clinical prevention of DOX-induced cardiotoxicity. Based on the theories of traditional Chinese medicine (TCM) on chronic heart failure (CHF), Shenlijia (SLJ), a new TCM compound, has been developed to fulfill multiple functions, including improving cardiac function and inhibiting cardiac fibrosis. In the present study, the protective effects and molecular mechanisms of SLJ on DOX-induced CHF rats were investigated. The CHF rat model was induced by intraperitoneal injection of DOX for six weeks with the cumulative dose of 15 mg/kg. All rats were then randomly divided into the control, CHF, CHF + SLJ (3.0 g/kg per day), and CHF + captopril (3.8 mg/kg per day) groups and treated for further four weeks. Echocardiography and the assessment of hemodynamic parameters were performed to evaluate heart function. A protein chip was applied to identify proteins with diagnostic values that were differentially expressed following SLJ treatment. The data from these investigations showed that SLJ treatment significantly improved cardiac function by increasing the left ventricular ejection fraction, improving the hemodynamic index, and inhibiting interstitial fibrosis. Protein chip analysis revealed that SLJ upregulated MCP-1, MDC, neuropilin-2, TGF-β3, thrombospondin, TIE-2, EG-VEGF/PK1, and TIMP-1/2/3 expressions and downregulated that of MMP-13. In addition, immunohistochemistry and western blot results further confirmed that SLJ promoted TIMP-1/2/3 and inhibited MMP-13 expression. The results of the present study suggest that SLJ was effective against DOX-induced CHF rats and is related to the improvement of heart function and ultrastructure and the inhibition of myocardial fibrosis.
format Online
Article
Text
id pubmed-8310442
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-83104422021-07-28 Shenlijia Attenuates Doxorubicin-Induced Chronic Heart Failure by Inhibiting Cardiac Fibrosis Sun, Xutao Song, Yunjia Xie, Ying Han, Jieru Chen, Fei Sun, Yang Sui, Bowen Jiang, Deyou Evid Based Complement Alternat Med Research Article Application of the anticancer drug doxorubicin (DOX) is restricted due to its adverse, cardiotoxic side effects, which ultimately result in heart failure. Moreover, there are a limited number of chemical agents for the clinical prevention of DOX-induced cardiotoxicity. Based on the theories of traditional Chinese medicine (TCM) on chronic heart failure (CHF), Shenlijia (SLJ), a new TCM compound, has been developed to fulfill multiple functions, including improving cardiac function and inhibiting cardiac fibrosis. In the present study, the protective effects and molecular mechanisms of SLJ on DOX-induced CHF rats were investigated. The CHF rat model was induced by intraperitoneal injection of DOX for six weeks with the cumulative dose of 15 mg/kg. All rats were then randomly divided into the control, CHF, CHF + SLJ (3.0 g/kg per day), and CHF + captopril (3.8 mg/kg per day) groups and treated for further four weeks. Echocardiography and the assessment of hemodynamic parameters were performed to evaluate heart function. A protein chip was applied to identify proteins with diagnostic values that were differentially expressed following SLJ treatment. The data from these investigations showed that SLJ treatment significantly improved cardiac function by increasing the left ventricular ejection fraction, improving the hemodynamic index, and inhibiting interstitial fibrosis. Protein chip analysis revealed that SLJ upregulated MCP-1, MDC, neuropilin-2, TGF-β3, thrombospondin, TIE-2, EG-VEGF/PK1, and TIMP-1/2/3 expressions and downregulated that of MMP-13. In addition, immunohistochemistry and western blot results further confirmed that SLJ promoted TIMP-1/2/3 and inhibited MMP-13 expression. The results of the present study suggest that SLJ was effective against DOX-induced CHF rats and is related to the improvement of heart function and ultrastructure and the inhibition of myocardial fibrosis. Hindawi 2021-07-16 /pmc/articles/PMC8310442/ /pubmed/34326887 http://dx.doi.org/10.1155/2021/6659676 Text en Copyright © 2021 Xutao Sun et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sun, Xutao
Song, Yunjia
Xie, Ying
Han, Jieru
Chen, Fei
Sun, Yang
Sui, Bowen
Jiang, Deyou
Shenlijia Attenuates Doxorubicin-Induced Chronic Heart Failure by Inhibiting Cardiac Fibrosis
title Shenlijia Attenuates Doxorubicin-Induced Chronic Heart Failure by Inhibiting Cardiac Fibrosis
title_full Shenlijia Attenuates Doxorubicin-Induced Chronic Heart Failure by Inhibiting Cardiac Fibrosis
title_fullStr Shenlijia Attenuates Doxorubicin-Induced Chronic Heart Failure by Inhibiting Cardiac Fibrosis
title_full_unstemmed Shenlijia Attenuates Doxorubicin-Induced Chronic Heart Failure by Inhibiting Cardiac Fibrosis
title_short Shenlijia Attenuates Doxorubicin-Induced Chronic Heart Failure by Inhibiting Cardiac Fibrosis
title_sort shenlijia attenuates doxorubicin-induced chronic heart failure by inhibiting cardiac fibrosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310442/
https://www.ncbi.nlm.nih.gov/pubmed/34326887
http://dx.doi.org/10.1155/2021/6659676
work_keys_str_mv AT sunxutao shenlijiaattenuatesdoxorubicininducedchronicheartfailurebyinhibitingcardiacfibrosis
AT songyunjia shenlijiaattenuatesdoxorubicininducedchronicheartfailurebyinhibitingcardiacfibrosis
AT xieying shenlijiaattenuatesdoxorubicininducedchronicheartfailurebyinhibitingcardiacfibrosis
AT hanjieru shenlijiaattenuatesdoxorubicininducedchronicheartfailurebyinhibitingcardiacfibrosis
AT chenfei shenlijiaattenuatesdoxorubicininducedchronicheartfailurebyinhibitingcardiacfibrosis
AT sunyang shenlijiaattenuatesdoxorubicininducedchronicheartfailurebyinhibitingcardiacfibrosis
AT suibowen shenlijiaattenuatesdoxorubicininducedchronicheartfailurebyinhibitingcardiacfibrosis
AT jiangdeyou shenlijiaattenuatesdoxorubicininducedchronicheartfailurebyinhibitingcardiacfibrosis